CpG DNA and cancer immunotherapy: Orchestrating the antitumor immune response

Current Opinion in Oncology

Volumn 15, Issue 6, 2003, Pages 440-445

  Wooldridge, James E ^a   Weiner, George J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Adjuvant; Cancer vaccine; CpG; DNA; Immunostimulatory sequences; Oligodeoxynucleotides

Indexed keywords

CPG 7909; DNA VACCINE; IBRITUMOMAB TIUXETAN; IMMUNOLOGICAL ADJUVANT; INTERFERON; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CPG ISLAND; DENDRITIC CELL; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DNA METHYLATION; DNA-BINDING PROTEINS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 9;

EID: 0742287262     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200311000-00006     Document Type: Review

References (56)

1. Wiemann B, Starnes CO: Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994, 64:529-564.
2. Mashiba H, Matsunaga K, Tomoda H, et al.: In vitro augmentation of natural killer activity of peripheral blood cells from cancer patients by a DNA fraction from Mycobacterium bovis BCG. Jpn J Med Sci Biol 1988, 41:197-202.
3. Yamamoto S, Yamamoto T, Shimada S, et al.: DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992, 36:983-997.
4. Krieg AM, Yi AK, Matson S, et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
5. Krieg AM: CpG motifs: the active ingredient in bacterial extracts? Nat Med 2003, 9:831-835. This article succinctly reviews the history and current status of CpG DNA.
6. Yi AK, Tuetken R, Redford T, et al.: CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998, 160:4755-4761.
7. Ahmad-Nejad P, Hacker H, Rutz M, et al.: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002, 32:1958-1968. Convincing and elegant studies of fluorescent-labeled CpG DNA using confocal microscopy in RAW264.7 macrophages demonstrate localization of CpG to intracellular compartments with colocalization of MyD88, suggesting that the biologic effect of CpG on cellular signaling begins with TLR9 and MyD88.
8. Hacker H, Vabulas RM, Takeuchi O, et al.: Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000, 192:595-600.
9. Schnare M, Holt AC, Takeda K, et al.: Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol 2000, 10:1139-1142.
10. Ashkar AA, Rosenthal KL: Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med 2002, 2:545-556.
11. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760. A comprehensive review of the biology and function of CpG DNA.
12. Yeo S-J, Gravis D, Yoon J-G, et al.: Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kB and p38. J Biol Chem 2003, published online.
13. Xu H, An H, Yu Y, et al.: Ras participates in CpG ODN signaling through association with TLR9 and promotion of IRAK1/TRAF6 complex formation in macrophages. J Biol Chem 2003, 278:36334-36340.
14. Hemmi H, Kaisho T, Takeda K, et al.: The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003, 170:3059-3064.
15. Hacker H: Signal transduction pathways activated by CpG-DNA. Curr Top Microbiol Immunol 2000, 247:77-92.
16. Krug A, Towarowski A, Britsch S, et al.: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001, 31:3026-3037.
17. Bernasconi NL, Onai N, Lanzavecchia A: A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003, 101:4500-4504. The expression of TLR9 in naïve B cells is lower than that seen on memory B cells, and TLR9 expression in naïve B cells is upregulated by stimulation of the BCR.
18. Hayashi F, Means TK, Luster AD: Toll-like receptors stimulate human neutrophil function. Blood 2003, published online. This article highlights the new finding that neutrophils express TLR9, and it serves as the basis for future work that is likely to confirm the importance of neutrophils in CpG DNA-induced immune stimulation.
19. Bernasconi NL, Traggiai E, Lanzavecchia A: Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202. An important article suggesting that memory cells can be stimulated by CpG DNA in the absence of signaling through the BCR. Furthermore, CpG DNA has limited ability to stimulate naïve B cells in the absence of stimulation through the BCR.
20. Yi A-K, Yoon J-G, Krieg AM: Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol 2003, 15:577-591. Signaling through the BCR and CpG-related pathways converge at multiple signaling pathways to augment secretion of interleukin-6, interleukin-10, and tumor necrosis factor-α while preventing BCR-mediated growth arrest and apoptosis.
21. van Ojik H, Bevart L, Dahle C, et al.: CpG-A and B ODN enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 2003, 63:5595-5600.
22. Lipford GB, Bendigs S, Heeg K, et al.: Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. Immunology 2000, 101:46-52.
23. Ballas ZK, Rasmussen WL, Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996, 157:1840-1845.
24. Zimmermann S, Heeg K, Dalpke A: Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3′ sequence modifications. Vaccine 2003, 21:990-995.
25. Ballas ZK, Krieg AM, Warren T, et al.: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001, 167:4878-4886.
26. Krug A, Rothenfusser S, Hornung V, et al.: Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31:2154-2163.
27. Redford TW, Yi AK, Ward CT, et al.: Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. J Immunol 1998, 161:3930-3935.
28. Yi AK, Chace JH, Cowdery JS, et al.: IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol 1996, 156:558-564.
29. Kemp TJ, Elzey BD, Griffith TS: Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003, 171:212-218. Induction of TRAIL/Apo-2L by CpG DNA on CD14+ macrophages may play a role in CpG-mediated effector activation and tumor killing.
30. Marshall JD, Fearon K, Abbate C, et al.: Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 2003, 73:781-792. This report suggests a new class of CpG DNA with the immune stimulation of both CpG-A and CpG-B.
31. Kawarada Y, Ganss R, Garbi N, et al.: NK- and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001, 167:5247-5253.
32. Sfondrini L, Besusso D, Zoia MT, et al.: Absence of the CD1 molecule upregulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J Immunol 2002, 169:151-158.
33. Heckelsmiller K, Rall K, Beck S, et al.: Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002, 169:3892-3899.
34. Sandler AD, Chihara H, Kobayashi G, et al.: CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 2003, 63:394-399. When administered with CpG-B, irradiated tumor cells engineered to secrete GM-CSF induced regression of established tumors and led to the development of a memory response.
35. Warren T, Wittrock C, McCaw M, et al.: CpG ODN capable of activating innate anti-tumor immunity induce development of an adaptive anti-tumor response when CpG ODN is administered in the presence of GM-CSF. Proceedings of the American Association for Cancer Research (AACR) 2003; 44 (1st ed): abstract 2006.
36. Wooldridge J, Link BK, Weisdorf DJ, et al.: Phase I study of oligodeoxynucleotide CpG 7909 in patients with previously treated non-Hodgkin's lymphoma. Proceedings of the American Society of Clinical Oncology (ASCO) 2003: abstract 843.
37. Hsu FJ, Caspar CB, Czerwinski D, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997, 89:3129-3135.
38. Bendandi M, Gocke CD, Kobrin CB, et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171-1177.
39. Weeratna R, Comanita L, Davis HL: CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol Cell Biol 2003, 81:59-62.
40. Cooper CL, Davis HL, Krieg AM, et al.: Improved hepatitis B vaccine response with CpG ODN 7909 adjuvant. Can J Infect Dis Suppl B 2001, 12: abstract 120.
41. Weiner GJ, Liu HM, Wooldridge JE, et al.: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 1997, 94:10833-10837.
42. Liu HM, Newbrough SE, Bhatia SK, et al.: Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998, 92:3730-3736.
43. Stern BV, Boehm BO, Tary-Lehmann M: Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J Immunol 2002, 168:6099-6105.
44. Davila E, Celis E: Repeated administration of cytosine- phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000, 165:539-547.
45. Davila E, Kennedy R, Celis E: Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003, 63:3281-3288. Synthetic peptide mimicking a tumor antigen and CpG DNA induced tumor regression more effectively when inhibitory CTLA-4 signals were blocked. This approach was not effective prophylactically, suggesting a need for an abundant source of tumor antigen.
46. Li WM, Dragowska WH, Bally MB, et al.: Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003, 21:3319-3329. Keeping antigen and CpG DNA together may enhance the effect, and liposomal encapsulation of a Her-2/neu peptide with CpG DNA appeared to be better than vaccination without encapsulation. The mechanism of delivery of effective agents may be very important in vaccination strategies.
47. Egeter O, Mocikat R, Ghoreschi K, et al.: Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000, 60:1515-1520.
48. Warren TL, Bhatia SK, Acosta AM, et al.: APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 2000, 165:6244-6251.
49. Brunner C, Seiderer J, Schlamp A, et al.: Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 2000, 165:6278-6286.
50. Heckelsmiller K, Beck S, Rall K, et al.: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002, 32:3235-3245. Peritumoral injections of CpG DNA combined with CpG-stimulated, antigen-pulsed DC at a distant site enabled the immune system to reject established tumors by inducing a tumor-specific CD8+ T-cell response.
51. Sato Y, Roman M, Tighe H, et al.: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273:352-354.
52. Rieger R, Kipps TJ: CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res 2003, 63:4128-4135.
53. Warren TL, Dahle CE, Weiner GJ: CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 2000, 1:57-61.
54. Wooldridge JE, Ballas Z, Krieg AM, et al.: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997, 89:2994-2998.
55. Decker T, Hipp S, Kreitman RJ, et al.: Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory- phosphorothioate oligodeoxynucleotides. Blood 2002, 99:1320-1326.
56. Jahrsdorfer B, Hartmann G, Racila E, et al.: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001, 69:81-88.